Kirn David sold $1.2M of FDMT
Kirn David (See Remarks) sold 114,746 shares of 4D Molecular Therapeutics, Inc. (FDMT) at $10.47 ($1.20M total) on 2026-06-22 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the specific open-market sale details (shares, price, total value) by an officer/director, executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note the insider sale for sentiment, but the 10b5-1 structure makes it less actionable as a fundamental signal.
What to watch
The filing does not indicate whether other insiders sold/bought around the same time, nor does it provide any new clinical or financial catalyst for FDMT.
Background
The article is a SEC Form 4 insider transaction disclosure for 4D Molecular Therapeutics, Inc.
Ticker impact
FDMT filed a Form 4 showing officer/director Kirn David sold 114,746 shares for about $1.20M under a pre-arranged 10b5-1 plan.
Low near-term impact; any reaction is likely limited to short-lived sentiment rather than a durable repricing.
The filing discloses transaction size, price, and that it was executed under a pre-arranged 10b5-1 plan, which reduces the signal of new negative information.
Market effects
Minimal. Insider sales under 10b5-1 generally do not change biotech sector fundamentals.
None indicated.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations, so traders may ignore it.
Key entities
- issuer4D Molecular Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderKirn David
Officer and director who sold shares in an open-market transaction under a 10b5-1 plan.
